Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Work from home jobs offer flexibility and extra cash to help pay off debt. Explore opportunities that fit your schedule.
25,050 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Bitcoin starts May above $80,000, reclaiming a key moving average and signaling renewed upside. This report breaks do...
Regulators press Binance to bolster anti-money-laundering controls as new findings tie more than $1 billion to Iran-l...
Arm is quietly becoming backbone of AI as it expands from smartphone CPUs into hyperscale data centers and edge devic...
A $222 million presale for Circle’s Arc token signals a strong institutional vote of confidence. Arc aims to underpin...
A fresh Mizuho note raises Intel's price target to $124 on AI server demand, signaling renewed confidence in the turn...
Putin addresses Zelensky ‘mister’ in a rare tone shift, a move Morgan Stanley calls a vibe shift in peace talks. Mark...
Snapdocs and BNY Mellon are rolling out an automated digital collateral and eCustody platform to streamline the mortg...
Gold is climbing as central banks snapping gold drives a new bid, with ETF buyers joining sovereign demand. This piec...
Bitcoin trades around $78,000 as PI token declines for a second straight weekend, fading hopes for a rebound. Analyst...
As growth ETFs pivot in 2026, the case for a tighter mega-cap tilt strengthens. This analysis weighs performance, con...
Ethereum retreats from a rough start to the year, but a key analyst says Crypto Spring has begun. Investors are watch...